Psychopharmacologic Agents and Electroconvulsive Therapy during Pregnancy and the Puerperium

  • Katherine L. Wisner
  • James M. Perel


The treatment of pregnant and lactating women with psychopharmacologic agents requires skilled decision making on the part of the psychiatric consultant. The physician must consider the benefits of pharmacotherapy compared to the risks it involves not only for the mother but also for the developing fetus. In assigning weights to the factors that enter the risk/benefit equation, the physician must be aware of data from the literature regarding medication administration during pregnancy. The objective of this chapter is to provide an overview of currently available data with respect to pharmacologic treatment during pregnancy and lactation for the major classes of medications used in psychiatric practice: antipsychotics, antidepressants, lithium, and antianxiety agents. Information on the use of electroconvulsive therapy (ECT) during pregnancy will also be reviewed.


Breast Milk Placental Transfer Lithium Toxicity Postpartum Psychosis Fluphenazine Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cupit GC, Rotmensch HH: Principles of drug therapy in pregnancy, in Gleicher N (ed): Principles of Medical Therapy in Pregnancy. New York, Plenum Press, 1985, pp 77–90.Google Scholar
  2. 2.
    Levy GH: Pharmacokinetics of fetal and neonatal exposure to drugs. Obstet Gynecol 58 (Suppl): 9S–16S, 1981.PubMedGoogle Scholar
  3. 3.
    Mirkin BL: Drug disposition and therapy in the developing human being. Pediatr Ann 5: 542–557, 1976.PubMedGoogle Scholar
  4. 4.
    Chao ST, Juchau MR: Placental drug metabolism, in Johnson EM, Kochhar DM (eds), Teratogenesis and Reproductive Toxicology. New York, Springer-Verlag, 1983, pp 31–48.Google Scholar
  5. 5.
    Soyka LF, Bigelow SW: Drug-metabolizing enzymes and their activity in the human fetus, in Stern L (ed): Drug Use in Pregnancy. Sydney, Australia, Adis Health Science Press, 1984, pp 17–44.Google Scholar
  6. 6.
    Finster M, Mark LC: Placental transfer of drugs and their distribution in fetal tissue, in Brodie BB, Gillette JR (ed): Basic Concepts in Biochemical Pharmacology. New York, Springer-Verlag, Berlin/Heidelberg, 1971, pp 276–285.Google Scholar
  7. 7.
    American Medical Association: Drug interactions and adverse drug reactions, in: AMA Drug Evaluations. Chicago, 1983, pp 31–44.Google Scholar
  8. 8.
    Wilson JG: Current status of teratology. General principles and mechanisms derived from animal studies, in Wilson JG, Fräser FC (eds): Handbook of Teratology, General Principles and Etiology, Vol. 1. New York, Plenum Press, 1977, pp 47–74.Google Scholar
  9. 9.
    Vorhees CV, Butcher, RE: Behavioral teratogenicity, in Snell K (ed): Developmental Toxicology. New York, Praeger, 1982, pp 249–298.Google Scholar
  10. 10.
    Werboff J, Gottlieb JS: Drugs in pregnancy: Behavioral teratology. Obstet Gynaec Survey 18: 420–423, 1963.Google Scholar
  11. 11.
    Coyle I, Wayner MJ, Singer G: Behavioral teratogenesis: A critical evaluation. Pharmac Biochem Behav 4: 191–200, 1976, 1976.Google Scholar
  12. 12.
    Hutchings DE: Behavioral teratology: A new frontier in neurobehavioral research, in Johnson EM, Kochhar DM (eds): Teratogenesis and Reproductive Toxicology. New York, Springer-Verlag, 1983, pp 207–235.Google Scholar
  13. 13.
    Brent RL: Methods of evaluating the alleged teratogenicity of environmental agents, in: Prevention of Physical and Mental Congenital Defects, Part C: Basic and Medical Science, Education, and Future Strategies. New York, Alan R. Liss, 1985, pp 191–195.Google Scholar
  14. 14.
    Cordero JF, Oakley GP: Drug exposure during pregnancy: Some epidemiologic considerations. Clin Obstet Gynecol 26: 418–428, 1983.PubMedGoogle Scholar
  15. 15.
    Bracken MB: Methodological issues in the epidemiologic investigation of drug-induced congenital malformations, in Bracken MB (ed): Perinatal Epidemiology. New York, Oxford University Press, 1984, pp 423–449.Google Scholar
  16. 16.
    FDA Drug Bulletin, Sept., pp 22–23, 1979.Google Scholar
  17. 17.
    Briggs GG, Bodendorfer TW, Freeman RK, et al: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Baltimore, Williams amp; Wilkins, 1983.Google Scholar
  18. 18.
    Gutheil TG: Improving patient compliance: Psychodynamics in drug prescribing. Drug Ther Hosp, July, pp 35–40, 1977.Google Scholar
  19. 19.
    Mogul KM: Psychological considerations in the use of psychotropic drugs with women patients. Hosp Comm Psychiatry 36: 1080–1085, 1985.Google Scholar
  20. 20.
    Hillard JR, Hillard PJA: Early diagnosis of pregnancy in a patient receiving antipsychotic medication. Am J Psychiatry 138: 9–10, 1981.Google Scholar
  21. 21.
    Davis JM, Janicak P, Chang S, et al: Recent advances in the pharmacologic treatment of the schizophrenic disorders, in Grinspoon L (ed): Psychiatry Update. The American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1982, pp 178–228.Google Scholar
  22. 22.
    Edlund MJ, Craig TJ: Antipsychotic drug use and birth defects: An epidemiologic reassessment. Corripr Psychiatry 25: 32–37, 1984.Google Scholar
  23. 23.
    Milkovich L, van den Berg BJ: An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125: 244–248, 1976.PubMedGoogle Scholar
  24. 24.
    Kris EB: Children born to mothers maintained on pharmacotherapy during pregnancy and postpartum. Recent Adv Biol Psychiatr 4: 180–187, 1961.Google Scholar
  25. 25.
    Kris EB: Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 7: 785–789, 1965.PubMedGoogle Scholar
  26. 26.
    Sobel DE: Fetal damage due to ECT, insulin coma, chlorpromazine, or reserpine. Arch Gen Psychiatry 2: 606–611, 1960.Google Scholar
  27. 27.
    Slone D, Siskind V, Heinonen OP: Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128: 486–488, 1977.PubMedGoogle Scholar
  28. 28.
    Rumeau-Rouquette C, Goujard J, Huel G: Possible teratogenic effect of phenothiazines in human beings. Teratology 15: 57–64, 1976.Google Scholar
  29. 29.
    Hall G: A case of phocomelia of the upper limbs. Med J Aust 1: 449–450, 1963.Google Scholar
  30. 30.
    Moriarty AJ, Nance MR: Trifluoperazine and pregnancy. Med J Aust 88: 375–376, 1963.Google Scholar
  31. 31.
    Rawlings WJ, Ferguson F, Maddison TG: Phenmetrazine and trifluoperazine. Med J Aust 1: 370, 1963.Google Scholar
  32. 32.
    Heinonen OP, Slone D, Shapiro S: Birth Defects in Pregnancy. Littleton, Publishing Sciences Group, 1977.Google Scholar
  33. 33.
    Scanlan FJ: The use of thioridazine (Melleril) [sic] during the first trimester. Med J Aust 1: 1271–1272, 1972.PubMedGoogle Scholar
  34. 34.
    Cleary MF: Fluphenazine decanoate during pregnancy. Am J Psychiatry 134: 815–816, 1977.PubMedGoogle Scholar
  35. 35.
    Donaldson GL, Bury RG: Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy. Acta Paediatr Scand 71: 335–338, 1982.PubMedGoogle Scholar
  36. 36.
    Kopelman AE, McCullar FW: Limb malformations following maternal use of haloperidol. JAMA 231: 62–64, 1975.Google Scholar
  37. 37.
    Hanson JW, Oakley GP: Haloperidol and limb deformity. JAMA 231: 26, 1975.PubMedGoogle Scholar
  38. 38.
    van Waes A, van de Velde E: Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 9: 224–227, 1969.Google Scholar
  39. 39.
    Donaldson JO: Control of chorea gravidarum with haloperidol. Obstet Gynecol 59: 381–382, 1982.PubMedGoogle Scholar
  40. 40.
    Patterson JF: Treatment of chorea gravidarum with haloperidol. Southern Med J 72: 1220–1221, 1979.PubMedGoogle Scholar
  41. 41.
    Hammond JE, Toseland PA: Placental transfer of chlorpromazine. Arch Dis Child 45: 139–140, 1970.PubMedGoogle Scholar
  42. 42.
    Scokel PW, Jones WN: Infant jaundice after phenothiazine drugs for labor: An enigma. Obstet Gynecol 20: 124–127, 1962.PubMedGoogle Scholar
  43. 43.
    Falterman CG, Richardson J: Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 97: 308–310, 1980.Google Scholar
  44. 44.
    Levy W, Wisniewski K: Chlorpromazine causing extrapyramidal dysfunction. NY State J Med 74: 684–685, 1974.Google Scholar
  45. 45.
    O’Connor M, Johnson GH, James DI: Intrauterine effect of phenothiazines. Med J Aust 1: 416–417, 1981.PubMedGoogle Scholar
  46. 46.
    Hill RM, Desmond MM, Kay JJ: Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 69: 589–595, 1966.PubMedGoogle Scholar
  47. 47.
    Desmond M, Rudolph AJ, Hill RM, et al: Behavioral alterations in infants born to mothers on psychoactive medication during pregnancy, in Farrell G (ed): Congenital Mental Retardation. Austin, Univ of Texas Press, 1969, pp 235–241.Google Scholar
  48. 48.
    Madsen JR, Campbell A, Baldessarini RJ: Effects of prenatal treatment of rats with haloperidol due to altered drug distribution in neonatal brain. Neuropharmacology 20: 931–939, 1981.PubMedGoogle Scholar
  49. 49.
    Whalley LJ, Blain PG, Prime JK: Haloperidol secreted in breast milk. Br Med J 282: 1746–1747, 1981.Google Scholar
  50. 50.
    Stewart RB, Karas B, Springer PK: Haloperidol excretion in human milk. Am J Psychiatry 137: 849–850, 1980.PubMedGoogle Scholar
  51. 51.
    Kris EB, Carmichael DM: Chlorpromazine maintenance therapy during pregnancy and confinement. Psychiatric Q 31: 690–695, 1957.Google Scholar
  52. 52.
    Herson MH, Barlow DH: Single Case Experimental Designs. Strategies for Studying Behavioral Change. New York, Pergamon Press, 1976.Google Scholar
  53. 53.
    Brown WA: Psychological Care during Pregnancy and the Postpartum Period. New York, Raven Press, 1979.Google Scholar
  54. 54.
    Kargas GA, Kargas SA, Bruyere HJ Jr, et al: Perinatal mortality due to interaction of dephenhydramine and temazepam, letter to editor. N Engl J Med 313: 14–17, 1985.Google Scholar
  55. 55.
    Saxen I: Cleft palate and maternal dephenhydramine intake. The Lancet 1: 407–408, 1974.Google Scholar
  56. 56.
    Parkin DE: Probable benadryl withdrawal manifestations in a newborn infant. J Pediatr 85: 580, 1974.PubMedGoogle Scholar
  57. 57.
    O’Brien TE: Excretion of drugs in human milk. Am J Hosp Pharm 31: 844–854, 1974.PubMedGoogle Scholar
  58. 58.
    Cole JO, Schatzberg AF: Antidepressant drug therapy, in Grinspoon L (ed): Psychiatry Update. The American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1983, pp 472–490.Google Scholar
  59. 59.
    Perel JM: Tricyclic antidepressant plasma levels, pharmacokinetics, and clinical outcome, in Grinspoon L (ed): Psychiatry Update. The American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1983, pp 490–511.Google Scholar
  60. 60.
    Edwards JG: Antidepressants and convulsions. The Lancet, December 22 /29, 1979, pp 1368–1369.Google Scholar
  61. 61.
    McBride WG: Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust 1: 492, 1972.PubMedGoogle Scholar
  62. 62.
    Australian Drug Evaluation Committee, Tricyclic antidepressants and limb reduction deformities. Med J Aust 1: 768–769, 1973.Google Scholar
  63. 63.
    Morrow AW: Limb deformities associated with iminodebenzyl hydrochloride. Med J Aust 1: 658–659, 1972.PubMedGoogle Scholar
  64. 64.
    Crombie DL, Pinsent RJ, Fleming D: Imipramine in pregnancy. Br Med J 1: 745, 1972.PubMedGoogle Scholar
  65. 65.
    Kuenssberg EV, Knox JDE: Imipramine in pregnancy. Br Med J 2: 292, 1972.PubMedGoogle Scholar
  66. 66.
    Scanion FJ: Use of antidepressant drugs during the first trimester. Med J Aust 2: 1077, 1969.Google Scholar
  67. 67.
    Sim M: Imipramine and pregnancy. Br Med J 2: 745, 1972.Google Scholar
  68. 68.
    Rachelefsky GS, Flynt JW Jr, Ebbin A, et al: Possible teratogenicity of tricyclic antidepressants. The Lancet 1: 838, 1972.Google Scholar
  69. 69.
    Banister P, DeFoe C, Smith ESO, et al: Possible teratogenicity of tricyclic antidepressants. The Lancet 1: 838–839, 1972.Google Scholar
  70. 70.
    Bracken MB, Holford TR: Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58: 336–343, 1981.PubMedGoogle Scholar
  71. 71.
    Eggermont E, Raveschat J, Deneve V, et al: The adverse influence of imipramine on the adaption of the newborn infant to extrauterine life. Acta Paediatr Belg 26: 197–204, 1972.PubMedGoogle Scholar
  72. 72.
    Webster PAC: Withdrawal symptoms in neonates associated with maternal antidepressant therapy. The Lancet 2: 318–319, 1973.Google Scholar
  73. 73.
    Gualtieri CT, Staye J: Withdrawal symptoms after abrupt cessation of amitriptyline in an 8-year-old boy. Am J Psychiatry 136: 457–458, 1979.Google Scholar
  74. 74.
    Petti TA, Law W: Abrupt cessation of high-dose imipramine treatment in children. JAMA 246: 768–769, 1981.PubMedGoogle Scholar
  75. 75.
    Law W, Petti TA, Kazdin AE: Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiatry 138: 647–650, 1981.PubMedGoogle Scholar
  76. 76.
    Dilsaver SC, Kronfol Z, Sackellares JC, et al: Antidepressant withdrawal syndromes: Evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacology 3: 157–164, 1983.Google Scholar
  77. 77.
    Shearer WT, Schreiner RL, Marshall RE: Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81: 570–572, 1972.PubMedGoogle Scholar
  78. 78.
    Sjoqvist F, Bergfors PG, Borga O, et al: Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: Evidence for drug metabolism. J Pediatr 80: 496–500, 1972.PubMedGoogle Scholar
  79. 79.
    Sovner R, Orsulak PJ: Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 136: 451–452, 1979.PubMedGoogle Scholar
  80. 80.
    Erickson SH, Smith GH, Heidrich F: Tricyclics and breast-feeding. Letters to the editor. Am J Psychiatry 136: 1483, 1979.PubMedGoogle Scholar
  81. 81.
    Orsulak R, Sovner PJ: Drs. Orsulak and Sovner reply. Letters to the editor. Am J Psychiatry 136: 1483, 1979.Google Scholar
  82. 82.
    Bader TF, Newman K: Amitriptyline in human breast milk and the nursing infant’s serum. Am J Psychiatry 137: 855–856, 1980.PubMedGoogle Scholar
  83. 83.
    Ananth J: The effects in the neonate from psychotropic agents excreted through breastfeeding. Am J Psychiatry 135: 801–805, 1978.PubMedGoogle Scholar
  84. 84.
    Brixen-Rasmussen L, Halgrener J, Jorgensen A: Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology 76: 94–95, 1982.PubMedGoogle Scholar
  85. 85.
    Verbeeck RK, Ross SG, McKenna EA: Excretion of trazodone in breast milk. Br J Clin Pharmacol 22: 367–370, 1986.PubMedGoogle Scholar
  86. 86.
    Kane FJ: Postpartum disorders, in Kaplan HI, Sadock BJ (eds): Comprehensive Textbook of Psychiatry IV. Baltimore, Williams amp; Wilkins, 1985, pp 1238–1242.Google Scholar
  87. 87.
    Hamilton JA: Guidelines for therapeutic management of postpartum disorders, in Inwood DG: Recent Advances in Postpartum Psychiatric Disorders. Washington, D.C., American Psychiatric Press, 1985, pp 83–96.Google Scholar
  88. 88.
    Oates M: The role of electroconvulsive therapy in the treatment of postnatal mental illness, in Cox JL, Kumar R, Margison FR et al: Current Approaches. Puerperal Mental Illness. Southampton, England, Duphar Laboratories Limited, 1986, pp 1–12.Google Scholar
  89. 89.
    Frank E, Kupfer DG, Jacob M, et al: Pregnancy-related affective episodes among women with recurrent depression. Am J Psychiatry 144: 288–293, 1987.PubMedGoogle Scholar
  90. 90.
    Schou M, Amdisen A, Streenstrup OR: Lithium and pregnancy—II, Hazards to women given lithium during pregnancy and delivery. Br Med J 2: 137–138, 1973.PubMedGoogle Scholar
  91. 91.
    Weinstein MR: Lithium treatment of women during pregnancy and in the post-delivery period, in Johnson FN (ed): Handbook of Lithium Therapy. Lancaster, England, MTP Press, 1980, pp 421–429.Google Scholar
  92. 92.
    Schou M: Practical problems of lithium maintenance treatment, in Kemali D, Racagni G (eds): Chronic Treatments in Neuropsychiatry. New York, Raven Press, 1985, pp 131–138.Google Scholar
  93. 93.
    Calabrese JR, Gulledge AD: Psychotropics during pregnancy and lactation: A review. Psychosomatics 26: 413–426, 1985.PubMedGoogle Scholar
  94. 94.
    Linden S, Rich CL,. The use of lithium during pregnancy and lactation. J Clin Psychiatry 44: 358–361, 1983.PubMedGoogle Scholar
  95. 95.
    Nora JJ, Nora AH, Towes WH., Lithium,Ebstein’s anomaly, and other congenital heart defects. The Lancet 2: 594–595, 1974.Google Scholar
  96. 96.
    Weinstein MR, Goldfield MD: Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132: 529–531, 1975.PubMedGoogle Scholar
  97. 97.
    Behrman RE, Vaughan VC (eds): Nelson’s Textbook of Pediatrics. Philadelphia, WB Saunders, 1983, pp 1136–1137.Google Scholar
  98. 98.
    Giuliani ER, Fuster V, Brandenburg RO, et al: Ebstein’s anomaly: The clinical features and natural history of Ebstein’s anomaly of the tricuspid valve. Mayo Clin Proc 54: 163–173, 1970.Google Scholar
  99. 99.
    Danielson GK, Fuster V: Surgical repair of Ebstein’s anomaly. Ann Surg 196: 499–503, 1982.PubMedGoogle Scholar
  100. 100.
    Anderson KR, Zuberbuhler JR, Anderson RH, et al: Morphologic spectrum of Ebstein’s anomaly of the heart: A review. Mayo Clin Proc 54: 174–180, 1979.PubMedGoogle Scholar
  101. 101.
    Wilson JG, Fräser FC (eds): Handbook of Teratology, General Principles and Etiology. New York, Plenum Press, 1977.Google Scholar
  102. 102.
    Long WA, Willis PW,: Maternal lithium and neonatal Ebstein’s anomaly: Evaluation with cross-sectional echocardiography. Am J Perinatol 1: 182–184, 1984.PubMedGoogle Scholar
  103. 103.
    Allan LD, Desai G, Tynan MJ: Prenatal echocardiography screening for Ebstein’s anomaly for mothers on lithium therapy. The Lancet, October 16, 1982, pp 875–876.Google Scholar
  104. 104.
    Kallen B, Tandberg A: Lithium and pregnancy. A cohort study on manic-depressive women. Acta Psychiatr Scand 68: 134–139, 1983.PubMedGoogle Scholar
  105. 105.
    Schou M: What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 54: 193–197, 1976.PubMedGoogle Scholar
  106. 106.
    Goodwin FK: Treatment of bipolar disorders, in Hales RE, Frances AJ (eds): Psychiatry Update. The American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1987, pp 81–107.Google Scholar
  107. 107.
    Jamison KR: Psychotherapeutic issues and suicide prevention in the treatment of bipolar disorders, in Hales RE, Frances AJ (eds): Psychiatry Update. The American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1987, pp 108–124.Google Scholar
  108. 108.
    Consensus Development Panel: Mood disorders: pharmacologic prevention of recurrences. NIMH/NIH consensus development panel statement. Am J Psychiatry 142: 469–476, 1985.Google Scholar
  109. 109.
    Gelenberg AJ: When a woman taking lithium wants to have a baby. Biol Ther Psychiatr 6: 19–20, 1983.Google Scholar
  110. 110.
    Morrell P, Sutherland GR, Buamah PK, et al: Lithium toxicity in a neonate. Arch Dis Child 58: 538–539, 1983.Google Scholar
  111. 111.
    Karlsson K, Lindstedt G, Lundberg PA, et al: Transplacental lithium poisoning: Reversible inhibition of fetal thyroid. The Lancet 1: 1295, 1975.Google Scholar
  112. 112.
    Stevens D, Burman D, Midwinter A: Transplacental lithium poisoning: Reversible inhibition of fetal thyroid. The Lancet 1: 1295, 1974.Google Scholar
  113. 113.
    Wilson N, Forfar JC, Godman MJ: Atrial flutter in the newborn resulting from maternal lithium ingestion. Arch Dis Child 58: 538–549, 1983.PubMedGoogle Scholar
  114. 114.
    Mizrahi EM, Hobbs JF, Goldsmith DI: Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatr 94: 493–495, 1979.PubMedGoogle Scholar
  115. 115.
    MacKay AVP, Loose R, Glen AIM: Labour on lithium. Br Med J, April 10, 1976, p 878.Google Scholar
  116. 116.
    Tunnessen WW Jr, Hertz CG: Toxic effects of lithium in newborn infants: A commentary. J Pediatr 81: 804–807, 1972.PubMedGoogle Scholar
  117. 117.
    Sykes PA, Quarrie J, Alexander FW: Lithium carbonate and breast-feeding. Br Med J 2: 1299, 1976.PubMedGoogle Scholar
  118. 118.
    Schou M, Amdisen A: Lithium and pregnancy—III, Lithium ingestion by children breast-fed by women on lithium treatment. Br Med J 2: 138, 1973.PubMedGoogle Scholar
  119. 119.
    Berlin CM: Pharmacologic considerations of drug use in the lactating mother. Obstet Gynecol 58 (Suppl): 17S–23S, 1981.PubMedGoogle Scholar
  120. 120.
    Targum SD, Davenport VB, Webster MJ: Postpartum mania in bipolar manic-depressive patients withdrawn from lithium carbonate. J Nerv Ment Dis 167: 572–574, 1979.PubMedGoogle Scholar
  121. 121.
    Post RM, Uhde TW: Clinical approaches to treatment resistant bipolar illness, in Hales RE, Frances AJ (eds): Psychiatry Update. American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1987, pp 125–150.Google Scholar
  122. 122.
    NIH Consensus Conference: Electroconvulsive therapy. JAMA 254: 2103–2108, 1985.Google Scholar
  123. 123.
    Repke JT, Berger NG: Electroconvulsive therapy in pregnancy. Obstet Gynecol 63 (Suppl): 39S–41S, 1984.PubMedGoogle Scholar
  124. 124.
    Varan LR, Gillieson MS, Skene DS, et al: ECT in an acutely psychotic pregnant woman with actively aggressive (homicidal) impulses. Can J Psychiatry 30: 363–367, 1985.PubMedGoogle Scholar
  125. 125.
    Wise MG, Ward SC, Townsend-Parchman W, Gilstrap LC, et al: Case report of ECT during high-risk pregnancy. Am J Psychiatry 141: 99–101, 1984.PubMedGoogle Scholar
  126. 126.
    Levine R, Frost EAM: Arterial blood-gas analyses during electroconvulsive therapy in a parturient. Anesth Analg 54: 203–205, 1975.PubMedGoogle Scholar
  127. 127.
    Impastato DJ, Gabriel AR, Lardara HH: Electric and insulin shock therapy during pregnancy. Dis Nerv Syst 25: 542–546, 1964.PubMedGoogle Scholar
  128. 128.
    Sobel DE: Fetal damage due to ECT insulin coma, chlorpromazine and reserpine. Arch Gen Psych 2: 603–611, 1960.Google Scholar
  129. 129.
    Fink M: Convulsive and drug therapies of depression. Ann Rev Med 32: 405–412, 1981.PubMedGoogle Scholar
  130. 130.
    Ostheimer G, Warren TM: Obstetric analgesia and anesthesia, in Stern L (ed): Drug Use in Pregnancy. Sydney, Australia, Adis Health Science Press, 1984, pp 216–269.Google Scholar
  131. 131.
    Remick RA, Maruice WL: ECT in pregnancy. Am J Psychiatry 135: 761–762, 1978.PubMedGoogle Scholar
  132. 132.
    Foldes FF: Enzymes of acetylcholine metabolism, in Foldes FF (ed): Enzymes in Anesthesiology. New York, Springer-Verlag, 1978, pp 101–144.Google Scholar
  133. 133.
    Kalow W, Gunn DR: The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exper Ther 120: 203–214, 1957.Google Scholar
  134. 134.
    Weis WF, Muller FO, Lyell H, et al: Materno-fetal Cholinesterase inhibitor poisoning. Anesth Analg 62: 233–235, 1983.PubMedGoogle Scholar
  135. 135.
    Moya F, Kvisselgaard N: The placental transmission of succinylcholine. Anesthesiology 22: 1–10, 1961.PubMedGoogle Scholar
  136. 136.
    Owens WD, Zeitlin GL: Hypoventilation in a newborn following administration of succinylcholine to the mother. Anesth Analg 54: 38–39, 1975.PubMedGoogle Scholar
  137. 137.
    Zbella EA, Gleicher N: Disorders of metal and metalloproteins, in Gleicher N (ed): Principles of Medical Therapy in Pregnancy. New York, Plenum, Press, 1985.Google Scholar
  138. 138.
    Brodie MJ, Moore MR, Thompson GG, et al: Pregnancy and the acute porphyrias. Br J Obstet Gynecol 84: 726–731, 1977.Google Scholar
  139. 139.
    Forssman H: Follow-up study of sixteen children whose mothers were given electric convulsive therapy during gestation. Acta Psychiatr Neurol Scand 30: 437–441, 1955.PubMedGoogle Scholar
  140. 140.
    Brockington IF, Winokur G, Dean C: Puerperal psychosis, in Brockington IF, Kumar R (eds): Motherhood and Mental Illness. London, Academic Press, 1980, pp 37–69.Google Scholar
  141. 141.
    Frank JD: The psychotherapy of anxiety, in: Psychiatry Update. American Psychiatric Association Annual Review. Washington, DC, American Psychiatric Press, 1984, pp 418–426.Google Scholar
  142. 142.
    Benson H: The relaxation response and the treatment of anxiety, in: Psychiatry Update. American Psychiatric Association Annual Review. Washington, DC, American Psychiatric Press, 1984, pp 440–448.Google Scholar
  143. 143.
    Mavissakalian M: Exposure treatment of agoraphobia, in: Psychiatry Update. American Psychiatric Association Annual Review. Washington, DC, American Psychiatric Press, 1984, pp 448–460.Google Scholar
  144. 144.
    Kanto JH: Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations. Drugs 23: 354–380, 1982.PubMedGoogle Scholar
  145. 145.
    Mandelli M, Morselli PL, Nordio S, et al: Placental transfer of diazepam and its disposition in the newborn. Clin Pharmacol Ther 17: 564–572, 1975.PubMedGoogle Scholar
  146. 146.
    Moore RG, McBride WG: The disposition kinetics of diazepam in pregnant women at parturition. Europ J Clin Pharmacol 13: 275–284, 1978.Google Scholar
  147. 147.
    Byck R: Drugs and the treatment of psychiatric disorders, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan Publishing Co, 1975, pp 152–299.Google Scholar
  148. 148.
    Kangas L, Erkkola R, Kanto J, et al: Transfer of free and conjugated oxazepam across the human placenta. Eur J Clin Pharmacol 17: 301–304, 1980.PubMedGoogle Scholar
  149. 149.
    Whitelaw AGL, Cummings AJ, McFadyen IF: Effect of maternal lorazepam on the neonate. Br Med J 282: 1106–1108, 1981.Google Scholar
  150. 150.
    Hauri PJ, Sateia MJ: Nonpharmacological treatment of sleep disorders, in Hales RE, Frances AJ (eds): Psychiatry Update. American Psychiatric Association Annual Review. Washington, DC, American Psychiatric Press, 1985, pp 361–394.Google Scholar
  151. 151.
    Mendelson WB: Pharmacological treatment of insomnia, in Hales RE, Frances AJ (eds): Psychiatry Update. American Psychiatric Association Annual Review. Washington, D.C., American Psychiatric Press, 1985, pp 379–394.Google Scholar
  152. 152.
    Milkovich L, van den Berg BJ: Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 291: 1268–1271, 1974.PubMedGoogle Scholar
  153. 153.
    Hartz SC, Heinonen OP, Shapiro S, Siskind V, Slone D: Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 292: 726–728, 1975.PubMedGoogle Scholar
  154. 154.
    Safra JM, Oakley GP: Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. The Lancet 2: 478–480, 1980.Google Scholar
  155. 155.
    Rosenberg L, Mitchell AA, Parsells JL, et al: Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 309: 1282–1285, 1983.PubMedGoogle Scholar
  156. 156.
    deHaan J, Van Bemmel JH, Stolte LAM, et al: Quantitative evaluation of fetal heart rate patterns. Europ J Obstet Gynecol 3: 103–110, 1971.Google Scholar
  157. 157.
    Yeh SY, Paul RIT, Cordero L, et al: A study of diazepam during labor. Obstet Gynecol 43: 363–373, 1974.PubMedGoogle Scholar
  158. 158.
    van Geijn HP, Jongsma HW, Doesburg WH, et al: The effect of diazepam administration during pregnancy or labor on the heart rate variability of the newborn infant. Eur J Obstet Gynecol Reprod Biol 10: 187–201, 1980.PubMedGoogle Scholar
  159. 159.
    Cree JE, Meyer J, Hailey DM: Diazepam in labour: Its metabolism and effect on the clinical condition and thermogenesis of the newborn. Br Med J 4: 251–255, 1973.PubMedGoogle Scholar
  160. 160.
    Gillberg C: “Floppy infant syndrome” and maternal diazepam. The Lancet 2:244, 1977.Google Scholar
  161. 161.
    Speight AN: Floppy-infant syndrome and maternal diazepam and/or nitrazepam. The Lancet 1: 878, 1977.Google Scholar
  162. 162.
    Volpe JJ: Teratogenic effects of drugs and passive addiction, in Volpe JJ (ed): Neurology of the Newborn. Philadelphia, WB Saunders Co., 1981, pp 601–635.Google Scholar
  163. 163.
    Rementeria JL, Bhatt K: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 90: 123–126, 1977.PubMedGoogle Scholar
  164. 164.
    Mazzi E: Possible neonatal diazepam withdrawal: A case report. Am J Obstet Gynecol 129: 586–587, 1977.PubMedGoogle Scholar
  165. 165.
    Athinarayanan P, Pierog SH, Nigam S, et al: Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol 124: 212–213, 1976.PubMedGoogle Scholar
  166. 166.
    Erkkola R, Kanto J: Diazepam and breast-feeding. The Lancet 2: 1235–1236, 1972.Google Scholar
  167. 167.
    Patrick MJ, Tilstone WJ, Reavey P: Diazepam and breast-feeding. The Lancet 1: 542–543, 1972.Google Scholar
  168. 168.
    Kumar R: Neurotic disorders in childbearing women, in Brockington IF, Kumar R (eds): Motherhood and Mental Illness. London, Academic Press, 1982, pp 71–118.Google Scholar
  169. 169.
    Perel JM, Glassman AH : unpublished data.Google Scholar
  170. 170.
    Nürnberg GH, Prudic J: Guidelines for treatment of psychosis during pregnancy. Hosp Comm Psych 35: 67–71, 1984.Google Scholar
  171. 171.
    Gelenberg A J: Pregnancy, psychotropic drugs, and psychiatric disorders. Psychosomatics 27: 216–217, 1986.PubMedGoogle Scholar
  172. 172.
    Margison F, Brockington IF: Psychiatric mother and baby units, in Brockington IF, Kumar R (eds): Motherhood and Mental Illness. London, Academic Pretfs, 1982, pp 223–238.Google Scholar
  173. 173.
    Kaplan MM: Thyroid disease in pregnancy, in Gleicher N (ed): Principles of Medical Therapy in Pregnancy. New York, Plenum Press, 1985, pp 192–211.Google Scholar
  174. 174.
    Ziegler VE, Knesevich JW, Wylie LT, et al: Sampling time, dosage schedule, and nortriptyline plasma levels. Arch Gen Psychiatry 34: 613–615, 1977.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Katherine L. Wisner
    • 1
  • James M. Perel
    • 2
  1. 1.Department of Psychiatry, Western Psychiatric Institute and ClinicUniversity of PittsburghPittsburghUSA
  2. 2.Departments of Psychiatry and Pharmacology, Western Psychiatric Institute and ClinicUniversity of PittsburghPittsburghUSA

Personalised recommendations